[The course of 203 superficial urothelial malignant tumors of the bladder during conservative treatment].
The authors present a total of 203 patients with histologically proven superficial bladder transitional cell cancer. Patients without recurrence had a follow-up longer than 12 months. The mean follow-up from the time of diagnosis was 35 months +/- 27 (standard deviation). Transurethral resection was not systematically followed by intravesical therapy. The following drugs were used: thiotepa, doxorubicin, BCG and rarely mitomycin C. Although BCG was generally used after failure of thiotepa or doxorubicin, it achieved the best results. 13 patients had a total cystectomy (6.4%). Patients without complete remission had a higher percentage of high grade and stage T1 tumors than patients without recurrence (the difference was statistically significant). The same applied to mortality: it was statistically more frequent in the first group than in the second group of patients.
de Jong
Z
Z
Service d'Urologie, CHU Ranqueil, Toulouse.
Pontonnier
F
F
Plante
P
P
Mansat
A
A
Centa
F
F
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology*; D009367:Neoplasm Staging; D012189:Retrospective Studies; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology
D000970:Antineoplastic Agents
Evolution sous traitement conservateur de 203 tumeurs malignes urothéliales superficielles de la vessie.